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Abstract
Human adipose stem cells (hASCs) play a crucial role in the fields of regenerative medicine and tissue engineering for
different reasons: the abundance of adipose tissue, their easy harvesting, the ability to multipotent differentiation and the
fact that they do not trigger allogeneic blood response or secrete cytokines that act as immunosuppressants. The vast
majority of protocols use animal origin reagents, with the underlying risk of transmitting infections by non-human
pathogens. We have designed a protocol to isolate and maintain the properties of hASCs avoiding xenogeneic reagents.
These changes not only preserve hASCs morphology, but also increase cell proliferation and maintain their stem cell marker
profile. On the other hand, human serum albumin (HSA), TrypleH and human Serum (HS), do not affect hASCs multipotent
differentiation ability. The amendments introduced do not trigger modifications in the transcriptional profile of hASCs,
alterations in key biochemical pathways or malignization. Thus, we have proven that it is possible to isolate and maintain
hASCs avoiding animal reagents and, at the same time, preserving crucial culture parameters during long term culture.
Thereby we have revealed a novel and effective tool for the improvement of clinical, cell-based therapies.
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Introduction
Mesenchymal stromal cells (MSCs) have been the most widely
used in preclinical and clinical assays so far[1–7]. MSCs can be
obtained from a variety of tissues [8–10], including the stromal
non-hematopoietic fraction of the bone marrow and adipose tissue
[11,12]. MSCs from bone marrow (BM-MSCs), have been
thoroughly described and characterized since they were the first
adult stem cell type identified and isolated [13]. A large number of
studies have analyzed the fate of adult stem cells administered in
vivo as well as the possible mechanisms by which they might
operate in the treatment of different diseases [6,14–18]. In most
procedures, isolated stem cells would need to be expanded in vitro
to obtain the number of cells required for clinical efficiency.
However, in vitro expansion increases the potential risk of
contamination and can also affect cell survival and function.
Among the MSCs obtained from other sources, human adipose
stem cells (hASCs) have emerged as strong candidates to play a
crucial role in the fields of regenerative medicine and tissue
engineering for several reasons. They can be easily harvested from
fat tissue, which is an abundant source. The cell yield per gram of
tissue is 500-fold that obtained for BM-MSCs [19,20]. They show
high rate of proliferation in vitro [12,21] and have the ability to
differentiate into several lineages: osteogenic, chondrogenic,
adipogenic and myogenic cells [11]. In addition, hASCs, like
their bone marrow counterparts, do not trigger the response of
allogeneic lymphocytes in vitro [22,23]. hASCs have also proven to
be successful, also for their ability to secrete cytokines, act as
immunosuppressants and activate antioxidant and angiogenic
pathways [20,24].
A number of clinical trials involving the treatment of a variety of
diseases hASC is already ongoing [14,22,25–29].
One of the key points for their use in clinics regards on the cell
isolation and expansion procedures. The vast majority of protocols
use reagents derived from animal sources, with the underlying risk
of transmitting infections by non-human pathogens [30,31].
Use of bovine derivatives (serum as supplement for cell growth
medium or serum albumin for cell washing saline solution) can
result in bacterial, viral and prion infections [32–36], or triggering
of an immunological reaction mediated by serum bovine proteins
[37,38]. Although little is known about other xenogeneic products,
as porcine-derived trypsin used for detaching cultured cells, those
products are likely to induce similar biosafety risks. The objective
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of our research was to design a protocol to isolate, expand and
maintain clinically safe and efficient hASCs, avoiding xenogenic
reagents. With this aim we replaced all animal reagents used for
isolation and maintainance by human or synthetic derivatives. To
validate the amendments, we compared the results obtained after
introduce the amendments, as well as gene expression profile of
the cells isolated and maintained in xenogeneic conditions.
Methods
Cell Harvesting and Culture Conditions
Human adipose tissue samples were obtained at private plastic
surgery clinic (Clinica Dra. Isabel Moreno) from lipoaspiration
procedures from 8 healthy patients under surgery by aesthetic or
beauty reasons (two of them were man and the rest were woman),
aged between 18 and 35, following written informed consent and
ethical research project approval by both Clinica Dra Isabel
Moreno and Principe Felipe Research Center (CIPF) ethical
boards. All the patients were previously screened for human
immunodeficiency virus (HIV), hepatitis C and other infectious
diseases. Cells were obtained following the protocol established
from Planat-Benard [7], with a few modifications. Briefly, samples
were digested in a solution of 1 mg/ml collagenase type I from
Clostridium Histolyticum (Gibco, Grand Island, NY) for 90
minutes at 37uC. The cells were then washed with 0.5% of HSA in
Hank’s balanced salt solution (Gibco, Grand Island, NY) and after
discarding mature adipocytes, seeded in culture flasks with growth
medium, Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with human or bovine serum mesenchymal stem
cell qualified (Gibco, Grand Island, NY), in a humidified
atmosphere of 95% air and 5% CO2 at 37uC. The medium was
replaced every 3 days. When primary culture became subcon-
fluent, cells were detached using TrypleH (Invitrogen) and
subcultured in growth medium.
Serum Collection and Storage
Human serum (HS) group A was obtained from voluntary
healthy blood donors at the Valencia Regional Transfusion
Centre. Donors were screened for disease risk factors using a
health history questionnaire and laboratory tests, fulfilling law
requirements for blood donations. Human sera (non lipemic and
negative for irregular antibody screening test) were pooled (80–100
donors), centrifuged (2900 g for 10 min) and stored at 230uC,
until use.
Experimental Design and Samples
We established four points of analysis per patient: isolation
point, that is, immediately after the isolation procedure; passage 1
(P1), or human adipose adherent cells after their first passage (3–5
days in culture); passage 3 (P3), after 10–12 days in culture); and
passage 5 (P5), following the fifth expansion around 20 days after
the isolation. This organization scheme was used throughout the
entire project for all experiments performed. The total number of
patients used in this study was n = 8, from which three were used
for the growth curve, proliferation assays and differentiation
experiments. Samples from the 8 patients were used for the rest of
studies.
Proliferation Kinetics
To assess the proliferative capacity of hASCs, parallel cultures
from three donors were analyzed through eleven serial passages
Figure 1. General scheme of the procedure highlighting the modifications introduced.
doi:10.1371/journal.pone.0067870.g001
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using two different culture conditions: 6% HS and 10% fetal
bovine serum (FBS). Cells were counted and subcultured every
four days. At each passage, the population doubling (PD) rate was
determined using the formula x = [log10(NH)- log10(N1)]/log10(2),
where N1 is the plated cell number and NH is the cell number at
harvest [8]. Cumulative population doubling rate was calculated,
adding to each passage the PD rate of the previous passages.
A growth curve was carried out in parallel using hASCs from
n = 3 donors, starting at passage 3. Two hundred cells per square
centimeter were plated in P24 plates (Beckton Dickinson). Every
day the cells from two wells were harvested and counted.
RT-PCR
hASCs from the 8 patients were analyzed for a list of genes
summarized on additional Table S1, using RT-PCR techniques.
H9 cells (Wicell) and commercial adipose tissue RNA (Stratagene)
were used as positive controls. Total RNA were extracted using
the RNeasy kit (Qiagen), according to manufacturer’s instructions,
and treated with DNAse (Qiagen). Total RNA obtained was
checked by spectroscopy using Nanodrop in order to assess the
quantity and purity acquired. An A260/A280 ratio between 1.8–2.0
was deemed optimal to accept the sample for experimental
procedures. Total RNA was then converted to cDNA through
reverse transcription using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems), in which the reaction
mixture contains 2 mg of total RNA, 2 mL of RT Buffer 10X, 2 mL
of Random Primers 10X, 0.8 mL of dNTPs and 1 mL of enzyme.
The reaction was adjusted to reach a final volume of 20 mL using
DEPC H2O. PCR using the synthesized cDNA was performed to
determine the presence or absence of the different transcripts.
PCR was carried out using an Eppendorf PCR machine and B-2
microglobulin, b-actin, or GAPDH were used as internal controls.
Electron Microscopy Studies
For fine ultrastructural analysis, cells were cultured in chamber
slides and then serially washed in a 0.1 M phosphate buffer (PB;
pH 7.4) solution, prior to their fixation for Transmission Electron
Microscopy (TEM). Fixation was performed in 3% glutaraldehyde
solution in PB for 30 minutes at 37uC and postfixed in 2% OsO4
in PB. Dehydration was achieved by a graded series of ethanol
solutions and a final rinse with propylene oxide (Lab Baker,
Deventry, Holland). Finally, plates were embedded in araldite
(Durkupan, Fluka) overnight. Following polymerization, embed-
ded samples were detached from the chamber slide and glued to
Araldite blocks. Serial semi-thin (1.5 mm) sections were cut with an
Ultracut UC-6 (Leica, Heidelberg, Germany), mounted onto slides
and finally stained with 1% toluidine blue. Ultrathin (0.07 mm)
sections were prepared with the Ultracut and stained with lead
citrate. Photomicrographs were obtained under a transmission
electron microscope (FEI Tecnai Spirit G2), using a digital camera
(Morada, Soft Imaging System,Olympus).
In Vitro Differentiation Assays
Differentiation assays into adipogenic and chondrogenic line-
ages were performed for hASCs from all culture conditions at
passage 1, from a total of n = 3 donors. The assay was then
repeated at passage 7 to determine whether cells differentiation
capacities were retained throughout long-term culture, following
protocols previously established [11]. Cartilage differentiation was
confirmed by histochemical staining using Alcian Blue and RT-
PCR screening for cartilage specific genes. Adipogenic differen-
tiation was induced in 100% confluent hASCs cultures with
induction media. The developing lipid vacuoles were stained with
Oil Red and specific genes for adipogenesis were screened for with
RT-PCR.
Figure 2. Morphology and expansion capacity of hASCs
cultured in 6%HS or 10% FBS. (A) Images of hASCs cultures at
days 1 and 4 after seeding (200 cells/cm2). Cells were obtained from the
same donor and cultured with 6% HS or 10% FBS, respectively (n = 3
donors). All the images were captured at 10X magnification in an
Olympus microscope. (B) Proliferation kinetics growth curve of hASCs in
HS and FBS from seeding until day 11. (C) Mean cumulative population
doublings for HS (black) and FBS (white). Cells used for both conditions
were obtained from the same 3 donors (n = 3) and cultured until
passage 18.
doi:10.1371/journal.pone.0067870.g002
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Microarray Data Analysis
Microarray analysis. Hybridization, washing, staining, and
scanning of the arrays was performed according to the manufac-
turer’s instructions (Agilent Technologies ‘‘one –color microarray-
based gene expression Analysis, 5.5 Version). The array contained
41000 probes.
Array design. We used total RNA obtained from lipoaspi-
rates of eight separate donors (aged 18–35 years). The samples
obtained from cell cultures consisted in total RNA isolated from
1.66106 cells. RNA was obtained using the RNeasy kit (Qiagen),
according to manufacturer’s instructions, and treated with DNAse.
RNA concentration was measured by spectroscopy using Nano-
drop with an A260/A280 ratio of 1.8. Prior to performing the
hybridization procedure Agilent p/n 5188–5977 ‘‘one-color
microarray-based gene expression analysis’’, we did a quality
and quantity control assay of total RNA, using electrophoresis in
an Agilent Bioanalizer. The RNA Integrity Number (RIN) was
between 8.0 and 9.9 in all the samples used for hybridization.
Total RNA was standardized among patients by pooling together
the different samples for each of the established stages. We
established four time points for the analysis (Isolation and passages
1, 3 and 5), using four primary culture RNA preparations from 4
different patients per time point. We repeated the hybridization
twice per group.Microarrays from hASC xenogeneic free cells are
deposited under GEO number GSE46314.
Microarray Gene Expression Data Analysis
Statistical analysis was carried out using the R-project software
[39] and the appropriate Bioconductor packages [40]. First
background correction was performed using the subtract function
implemented in the R package named Limma [41]. Then, and in
order to remove all the possible sources of variation of a non-
biological origin, densitometry values were transformed into a
logarithmic binary scale and then, they were normalized between
arrays using the normalize Quantiles function also implemented in
the Limma package.
Statistically significant differences between groups were identi-
fied using the empirical Bayes method, also implemented as eBayes
function in Limma package to moderate the standard errors of the
estimated log-fold changes. This results in more stable inference
and improved power, especially for experiments with small
numbers of arrays. This approach includes the Benjamini-
Hochberg (BH) multiple hypotheses test using the Bioconductor
multtest package for raw p-value correction to ascertain the false
positive rate. Those genes showing a BH p-value,0.05 were
selected as de-regulated genes. Functional annotations were
carried out using the Database for Annotation, Visualization and
Integrated Discovery (DAVID) [42], which allows the searching
for blocks of functionally-related genes by different criteria such as
the Gene Ontology terms and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways, among others. Finally, functional
Networks were obtained using the Ingenuity Pathway Analysis
(IPA; Ingenuity Systems, RedwoodCity, CA) [43], in which the
gene symbols and the up- and down-regulated significant genes
(Tables 1, 2, 3 and 4) were imported.
Figure 3. Characterization and comparison of hASC HS/FBS maintained. (A) RT-PCR analysis of gene expression in hASCs cultured for 3 and
5 passages on either HS or FBS. Adipose tissue markers or human adipose stem cell markers (respectively). (B) Analysis of the morphology of the
hASCs cultured under our protocol at passages 1, 3 and 5 respectively. For these structural studies semi-thin sections stained with toluidine blue were
used. All the images were captured in a Zeiss Axiovert 200 M microscope. Magnification= 100 X.
doi:10.1371/journal.pone.0067870.g003
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Results
Effect of Human Serum and Non-animal Reagents in
hASCs Isolation and Maintenance
Immediately after their obtention in the surgery room,
lipoaspirates (>3 l per patient), were transported to the laboratory
and splitted in 2 sterile containers inside a culture hood. For
digestion, one was treated with human derivatives (HSA for
washing and HS during seeding) and the other with bovine
reagents (BSA and FBS). After discard blood derivatives, mature
adipocytes and chirurgical infiltration solution, the isolated hASC
fractions were seeded under their respective conditions (for
summary of the protocol see Fig. 1) to evaluate differences
between both protocols. After four days, the cells maintained their
characteristic fibroblastic morphology [20,21]. In contrast, FBS-
hASCs showed smaller cellular density, or larger cell size (Fig. 2
A). In order to determine the optimal HS concentration required
in the media, alamar blue assay was performed to check cell
viability and proliferation. Human serum concentration percent-
ages used were 0, 3, 6 and 10. Based on the growth results
obtained, 6% HS concentration was chosen (data not shown).We
were using TrypleH for detaching and reseeding the cells.
Growth Curve and Culture Evolution across Time
Based on previous studies [21], we established a growth curve
by seeding passage 3 cells in two groups, with HS or FBS
Figure 4. Differentiation ability of HS maintained hASC. Phase contrast images of hASCs subjected to a chemically-defined method for
differentiation to adipose and cartilage tissues.Results corresponds to differentiation protocols triggered in cells at 7 passage. (A) Oil red O staining of
hASCs adipose differentiated cultures on day 12 of differentiation protocol and their corresponding controls, (B) Scale bars: 50 mm, (C) Alcian-Blue
staining for cartilage precursors obtained after 15 days culturing hASCs with specific differentiation protocols or in control media, (D) Scale bars:
100 mm. (E–J) Transmission electron microscopy characterization of adipocytes (E, H), cartilage (F,I) and control cells (G, J) obtained from hASCs
after the differentiation protocol. Scale bars: 5 mm. (K) Analysis of adipocyte differentiation markers using RT-PCR. At the time of terminal
differentiation culture time, mRNA was prepared for analysis by PCR. Products were visualized by gel electrophoresis. (L) Analysis of cartilage
differentiation markers using RT-PCR.
doi:10.1371/journal.pone.0067870.g004
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respectively, in a density of 200 cells per square centimeter. Cell
counting was performed on a daily basis from day 4 until day 11.
Use of HS increased proliferation, which added difficulty for
evaluating confluence. HS-hASCs proliferated sooner and faster
than those cultured in FBS (Fig. 2 B)(day 0–1 versus day 4
respectively). Concerning the growth curve, the rate of prolifer-
ation reached its peak between day 4 (9.3610363.76103 cells/
cm2 or 3.03 fold the previous measurement) and day 6
(5.1610464.16103 cells/cm2 or 1.8 fold) in HS maintained cells.
During this period, the population-doubling time (PDT) for cells
maintained with HS was less than 24 hours. HS-hASCs began to
reach confluence after this point and the rate of proliferation
decreased, limited by a cell-density phenomenon, reaching a total
of 7.8610463.86103 cells/cm2 at day 11. Cells on day 11 were
grouped in parallel, an indication that they were entering the
plateau phase. In contrast, FBS-hASCs proliferated around day 4
(1.43610263.16100 cells/cm2 or 1.65 fold), with a progressive
increase in their rate of division until day 7 (4.06610267.96101
cells/cm2 or 1.38 fold). The rate of division for FBS-hASCs is
lower than that for HS-hASCs. PDT for FBS-hASCs is also longer
than for HS-hASCs in the middle of the log phase growth. These
results confirm that HS has a high proliferation induction effect.
Concerning proliferation kinetics, comparison of the expansion
rates for HS-hASCs and FBS-hASCs showed significant differ-
Figure 5. Ingenuity network analysis constructed using significant up-regulated genes (BH,0.05) founded during hASC culture
evolution. The top network functions were Regulation of actin cytoskeleton, ECM-receptor interaction, cell division signaling pathway and
ribosome. ABI1 = abl-interactor 1; ABL1 = c-abl oncogene 1, receptor tyrosine kinase; AKAP13=A-kinase anchor protein 13; CASP8AP2= caspase 8
associated protein 2; caspase = apoptosis -related cystein peptidase; CEBPA=CCAAT/enhancer-binding protein alpha; CHEK1=CHK1 checkpoint
homolog (S. pombe); CLEC11A=C-type lectin domain family 11; CRHR1= corticotropin-releasing factor receptor 1; DYNLT3= dynein light chain Tctex-
type 3; ERK1/2 =mitogen activated protein kinase; FAS = Fas (TNF receptor superfamily, member 6); FGF2= fibroblast growth factor 2 (basic);
FN1= fibronectin 1; GLO1=glyoxalase I; IL36A= interleukin-36 alpha; IL36B= interleukin-36 beta; IL36G= interleukin-36 gamma; LITAF= lipopoly-
saccharide-induced TNF factor; MICA=MHC class I polypeptide-related sequence A; NFkB=NF-kappa-beta; P2RY6=pyrimidinergic receptor P2Y, G-
protein coupled, 6; PFN2=profilin-2; Pkc(s) = protein kinase C; PPP2RA=protein phosphatase 2; RIN1= ras and Rab interactor 1; RPLP0= ribosomal
protein, large, P0; RRAS2 = related RAS viral (r-ras) oncogene homolog 2; SATB1 =DNA-binding protein SATB1; SDC1 = syndecan 1;
SMPD2= sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase); Sphk= sphingosine kinase; WASF1=WAS protein
family, member 1; WASF2=WAS protein family, member 2; WASF3=WAS protein family, member 3.The grey nodes are the genes classified as
significant. The asterisk (*) indicates the degree of up-regulation.
doi:10.1371/journal.pone.0067870.g005
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ences (Fig. 2 C). Since the first moment, HS-cultured cells start to
show a strong proliferative capacity, with levels of 33.964.1
cumulative population doublings at passage 18. At the same time
point, FBS-maintained cells reached levels of 13.963.3 cumulative
population doublings and the proliferation rate decreased imme-
diately. These differences in proliferation kinetics between hASCs
cultured on FBS or HS were clear and consistent since the first
passage and in all the samples.
Morphological and Molecular Biology Characterization of
hASC Obtained with the Improvements of the Protocol
hASCs were analyzed by PCR for transcriptional evidence of
genes associated with adipose mesenchymal stem cells, early
development, hematopoietic and adipose tissue markers [see Table
S1].
We wanted to confirm that cells were expressing markers
characteristic of their germ layer and undifferentiated state. We
followed the evolution of these markers throughout the culture,
analyzing the cells at passages 3 and 5. We first analyzed (Fig. 3 A)
the expression of adipose tissue markers. We discarded the mature
adipocyte fraction during hASCs isolation process, to make sure
that only the stromal vascular fraction was obtained. We searched
for specific markers of terminally differentiated adipose cells -
Adiponectin, Leptin and Adducin 1 (ADD1) - or genes enrolled in
terminal differentiation processes such as fatty acid synthesis and
storage of lipid droplets (AP2 and Perilipin, respectively). The
results obtained (Fig. 3 A) indicate that with the exception of
ADD1, which did not seem to be expressed in any stage of the
culture, mature adipose cell markers such as Adiponectin, Leptin,
Perilipin and AP2 were clearly expressed following isolation.
However, expression levels for these markers gradually decreased
throughout maintenance of the culture. Markers for early white
Figure 6. Ingenuity network analysis constructed using significant down-regulated genes (BH,0.05) founded during hASC culture
evolution. The top network functions were Hematopoietic cell lineage, Cell adhesion molecules, Leucocyte transendothelial migration and
Complement and coagulation cascades. B2M=beta-2-microglobulin; BCR=breakpoint cluster region; CD14=monocyte differentiation antigen CD14;
CD3= T-cell surface glycoprotein CD3 epsilon chain; EPOR= erythropoietin receptor; ERK1/2 =mitogen activated protein kinase; EZR= ezrin;
F13A1= coagulation factor XIII, A1 polypeptide; FCRLA= Fc receptor-like A; FXN= frataxin, nuclear gene encoding mitochondrial protein;
FYN= tyrosine-protein kinase Fyn; GRM1=glutamate receptor, metabotropic 1; GZMB=granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated
serine esterase 1); HBEGF= heparin-binding EGF-like growth factor; HLA-DRB1=MHC class II antigen HLA-DRB1 beta 1; HLA-F =HLA class I
histocompatibility antigen, alpha chain F; IFNGR1 = Interferon gamma receptor 1; IGF1 = insulin-like growth factor 1 (somatomedin C);
IL10RA= interleukin 10 receptor, alpha; IL13 = interleukin 13; IL1R2= interleukin 1 receptor, type I; Immunoglobulin = Immunoglobulin; Karyopherin
beta = nucleo cytoplasmic transporter; lgG= inmunoglobulin G; lgm= immunoglobulin M; Mapk=Mitogen-activated protein kinase; NFKB=NF-
kappa-beta; NFKB1= nuclear factor NF-kappa-B p105 subunit; P38MAPK=map kinase p38; PI3K = phosphatidylinositol 4-phosphate 3-kinase;
PIK3R3=phosphatidylinositol 3-kinase regulatory subunit gamma; PLCG2= 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2;
STAT5A= signal transducer and activator of transcription 5B; TCR= T cell antigen receptor; VEGF= vascular endothelial growth factor. The grey nodes
are the genes classified as significant. The asterisk (*) indicates the degree of down-regulation.
doi:10.1371/journal.pone.0067870.g006
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adipocyte development and adipocyte progenitor presence such as
adipose differentiation-related protein (ADFP), lipoprotein lipase
(LPL) and peroxysome proliferator activated receptor (PPAR)
were also analyzed. These genes were expressed during the
isolation, maintenance and expansion of the cultures (Fig. 3 A).
We next analyzed the expression of mesenchymal stem cell
markers (Fig. 3 A). Both cells cultured with HS and FBS, were
positive for CD90, CD73, CD29, CD105, CD13, CD166. In
primary cultures from one sample, cells showing positive results for
CD14 and CD45 haematopoietic markers were observed (due to
themonocyte/macrophage from peripheral blood). In addition,
this culture evidenced the presence of CD34 positive cells from the
endothelial lineage. The level of expression of these markers was
progressively down regulated (CD14 and CD45) or completely
disappearing (CD34) by washings and passages or overgrown by
the mesenchymal stromal fraction [See Figure S2]. Flow
cytometry was used in parallel to assess the mesenchymal profile.
In the absence of animal derivatives, more than 90% of the hASC
obtained [see flow cytometry analysis and table in Figure S1]
conserve their characteristic surface markers levels for CD90,
CD73 and CD44. We did not observe differences between cells
cultured with HS or FBS in terms of the percentage of
mesenchymal marker expression.
To fully characterize the procedure, a morphological analysis of
the cells was also required. Optical microscopy did not reveal
major differences between cells cultured with HS versus those
cultured with FBS. A more detailed study of the morphology at a
semithin section level (Fig. 3 B) allowed us to visualize the
evolution of the cells between passages 1, 3 and 5. The majority of
the cells in passage 1 exhibit an elongated cellular body, with an
oval-shaped nucleus with packed chromatin and several well-
developed nucleoli. Their cytoplasm was lightly granular,
containing a large number of organelles. At passage 3, cellular
morphology was mostly fusiform, but we did observe a reduced
number of star-shaped and small cells. The spherical nucleus
contained several well-developed nucleoli and lightly-packed
chromatin. The cytoplasm was more granular than in passage 1.
At passage 5, cellular bodies became polymorphic with a lightly
oval-shaped nucleus, characterized by lax chromatin. Mitosis was
frequently observed in all 3 stages. We did not observe
multinucleated, giant or other abnormal cells.
Differentiation Ability
To determine whether the lack of animal reagents could
diminish this potential, we performed differentiation assays using
protocols previously established, to trigger differentiation towards
the adipose and chondrogenic lineages [11]. hASCs at passage 3
and 7 were transferred to adipocyte induction media for 10 days
and analyzed for lipid accumulation, morphological ultrastructure
characterization and RT-PCR for adipose tissue markers. We
observed the presence of abundant oil red O-stained lipid droplets
in the cytoplasm of cells maintained with adipogenic differentia-
tion media (Fig. 4 A), in contrast to their corresponding controls
(Fig. 4 C). Detailed ultrastructure analysis using TEM revealed
that their morphology was compatible with mature adipocytes.
Semithin sections (Fig. 4 E) allowed us to observe cells with their
cytoplasm saturated with lipid droplets and an eccentric nucleus,
in contrast to their corresponding controls, fusiform cells with a
granular cytoplasm and an oval nucleus (Fig. 4 G, J). Differen-
tiated cells were round and smaller with big lipid droplets,
surrounded by a fully developed rough endoplasmic reticle rER
(Fig. 4 H). Dense bodies were observed in the cytoplasm of control
cells. See (Fig. 4 J). In addition and supporting these observations,
differentiated cells expressed the typical gene expression pattern of
mature adipocytes (Fig. 4K).
Table 1. Up-regulated genes between passages involved in significant KEEG pathways.
Number of
genes BH,0.05 KEGG Pathway Genes in KEGG pathway
Fisher exact
p-value
Passage 1 versus Isolation 63 ECM-receptor interaction COL1A2, FN1,SDC1 2.5?1023
Biosynthesis of unsaturated
fatty acids
ELOVL6, FADS1 2.3?1023
Passage 3 versus passage 1 111 Piruvate metabolism ACAT2, ALDH1B1, PDHB 1.3?1023
Butanoate metabolism E2F5,SMAD2,ANAPC1,CDC16,CDNK2A, ORC4L,TFDP2 1.0?1024
Cell cycle ACAT2, ALDH1B1, GLO1, PDHB 1.1?1024
Passage 5 versus passage 3 209 Cell division pathway BBC3, CHEK1, FAS, THBS1 7.2?1023
Ribosome MRPL13, RPL22L1, RPS10, RPLP0 1.7?1022
Pyruvate metabolism ACAT2, ALDH7A1, ME1 1.0?1022
Regulation of actin cytoskeleton WASF1, CFL2, FGF2, PFN2, RRAS2 3.5?1022
doi:10.1371/journal.pone.0067870.t001
Table 2. Down-regulated genes between passage 1 versus isolation which are involved in significant KEEG pathways.
Number of genes BH,0.05 KEGG Pathway Genes in KEGG pathway Fisher exact p-value
97 Jak-STAT Signaling pathway EZR, JAM PIK3R3 1.0?1022
Leucocyte transendothelial migration ARGDIB,NTRK2 PIK3R3 1.2?1022
Neurotrophin signalling pathway IFNGR1,LIFR, PIK3R3 SPRY1 2.7?1023
doi:10.1371/journal.pone.0067870.t002
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Chondrocyte differentiation was induced with specific media [9]
during 15 days. Alcian blue staining confirmed the presence of
proteoglycans secreted by cartilage differentiated cells in cultures
treated with the differentiation media (Fig. 4 B), but not in their
corresponding controls (Fig. 4 D). Semithin sections (Fig. 4 F)
showed that differentiated cells were elongated with an eccentric
Table 3. Down-regulated genes between passage 3 versus passage 1 which are involved in significant KEEG pathways.
Number of genes BH,0.05 KEGG Pathway Genes in KEGG pathway Fisher exact p-value
136 Neurotrophin signaling pathway PLCG2, NTRK2, NFKB1, PIK3R3, ARHGDIB 2.1?1023
Epithelial cell signaling in Helicobacter
pylori infection
PLCG2, HBEGF, NFKB1, JAM2 1.5?1023
Viral myocarditis HLA-DRB1, FYN, HLA-DMA, HLA-DQA1 1.8?1023
Cell adhesion molecules (CAMs) HLA-DRB1, CD34, JAM2, HLA-DMA, HLA-DQA1 2.8?1023
Asthma HLA-DRB1, HLA-DMA, HLA-DQA1 1.2?1023
Antigen processing and presentation HLA-DRB1, HLA-DMA, HLA-DQA1, B2M 3.2?1023
Hematopoietic cell lineage IL1R2, HLA-DRB1, CD34, CD14 3.6?1023
ErbB signaling pathway PLCG2, HBEGF, PIK3R3, NRG2 3.8?1023
Allograft rejection HLA-DRB1, HLA-DMA, HLA-DQA1 2.3?1023
Graft-versus-host disease HLA-DRB1, HLA-DMA, HLA-DQA1c¸ 2.9?1023
Type I diabetes mellitus HLA-DRB1, HLA-DMA, HLA-DQA1 3.6?1023
Intestinal immune network for IgA
production
HLA-DRB1, HLA-DMA, HLA-DQA1 5.6?1023
Autoimmune thyroid disease HLA-DRB1, HLA-DMA, HLA-DQA1 6.3?1023
Leukocyte transendothelial migration EZR, PLCG2, PIK3R3, JAM2 1.1?1022
Pathogenic Escherichia coli infection EZR, FYN, CD14 8.5?1023
Adipocytokine signaling pathway NFKB1, POMC, CAMKK2 1.3?1022
Complement and coagulation Cascades VWF, F13A1, CFH 1.4?1022
doi:10.1371/journal.pone.0067870.t003
Table 4. Down-regulated genes between passage 5 versus passage 3 which are involved in significant KEEG pathways.
Number of genes
BH,0.05 KEGG Pathway Genes in KEGG pathway Fisher exact p-value
237 Cell adhesion molecules (CAMs) ITGA9, PTPRM, HLA-DRB1, CD34, CLDN5, HLA-DRB5, HLA-DPB1,
JAM2, HLA-DMA, HLA-DQA1, HLA-F
5.5?1027
Allograft rejection HLA-DRB1, HLA-DRB5, GZMB, HLA-DPB1, HLA-DMA, HLA-DQA1,
HLA-F
2.2?1027
Graft-versus-host disease HLA-DRB1, HLA-DRB5, GZMB, HLA-DPB1, HLA-DMA, HLA-DQA1,
HLA-F
4.0?1027
Type I diabetes mellitus HLA-DRB1, HLA-DRB5, GZMB, HLA-DPB1, HLA-DMA, HLA-DQA1,
HLA-F
6.8?1027
Asthma HLA-DRB1, IL13, HLA-DRB5, HLA-DPB1, HLA-DMA, HLA-DQA1 1.2?1026
Autoimmune thyroid disease HLA-DRB1, HLA-DRB5, GZMB, HLA-DPB1, HLA-DMA, HLA-DQA1,
HLA-F
2.7?1026
Antigen processing and presentation HLA-DRB1, HLA-DRB5, HLA-DPB1, HLA-DMA, HLA-DQA1, B2M,
HLA-F
7.0?1025
Hematopoietic cell lineage IL1R2, HLA-DRB1, CD34, CD33, HLA-DRB5, EPOR, CD14 8.8?1025
Viral myocarditis HLA-DRB1, HLA-DRB5, HLA-DPB1, HLA-DMA, HLA-DQA1, HLA-F 2.4?1024
Intestinal immune network for IgA
production
HLA-DRB1, HLA-DRB5, HLA-DPB1, HLA-DMA, HLA-DQA1 3.4?1024
Systemic lupus erythematosus HLA-DRB1, HLA-DRB5, HLA-DPB1, HLA-DMA, HLA-DQA1 7.8?1023
Jak-STAT signaling pathway SPRY1, IL10RA, STAT5A, IL13, EPOR, PIK3R3 1.3?1022
Aldosterone-regulated sodium
reabsorption
HSD11B2, IGF1, PIK3R3 1.4?1022
ErbB signaling pathway STAT5A, HBEGF, PIK3R3, NRG2 2.3?1022
doi:10.1371/journal.pone.0067870.t004
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nucleus, generally containing two nucleoli (Fig. 4 F). Fibers were
abundant in differentiated cultures, and occasionally formed
aggregates (Fig. 4 F). In contrast, controls (Fig. 4 G) conserved
their characteristic fusiform shape and lacked the presence of
fibers between cells (or around). Electron microscopy studies
allowed to observe in detail that the above mentioned fibers in
differentiated cells were secreted as extracellular matrix and had a
typical collagen organization (Fig. 4 I). Fibers were not detected in
control cultures (Fig. 4 J). These results were further confirmed by
analysis of gene expression (Fig. 4 L). Differentiated hASCs
expressed specific cartilage markers as Aggrecan1 and 2.
Expression of other markers such as CN10 or Biglican was
increased in differentiated hASCs versus control. No differences in
terms of percentage or differentiation ability were observed
between hASCs treated on passage 3 versus passage 7.
Microarray Analysis
To further characterize possible changes or abnormalities
induced in the cells by the increase of proliferation kinetics, we
next studied their transcriptional profile evolution during culture
with HS, using microarrays to compare possible variations of their
profile in the different passages [Analysis and data available are
provided at Text S1, and Table S2 and Figure S2]. Detailed
results of the microarray gene expression in HS cultured cells,
following comparison between passages, are shown in Tables 1, 2,
3, 4 and 5. Internal controls resulted as expected for each array.
From a total of probes we paid attention to the intragroup gene
expression differences between passages. Concerning significant
up-regulation events (BH p-value ,0.05), as shown on Table 1, we
found 63 genes up-regulated on passage 1 versus the moment of
isolation, 111 on passage 3 versus passage 1 and 209 on passage 5
versus passage 3. Regarding significant down-regulation (BH p-
value ,0.05), we detected 97 genes from passage 1 to passage 0,
136 from passage 3 to passage 1 and 237 from passage 5 to passage
3 (see Table 2, 3 and 4). Once the differences in the expression
patterns between passages were obtained, we wanted to determine
any possible relationships between the up- regulated and down-
regulated genes, in order to identify any functional or molecular
pathways involved. To determine such relations we used DAVID
bioinformatics resources [42,44]. KEGG was used to link the
genes obtained with potential biological processes in which hASCs
could be involved. The KEGG pathways found were compiled in
Tables 1, 2, 3, 4 and 5. Summarizing, up-regulated genes (Table 1)
observed when comparing cells processed immediately after
isolation (G0) to their counterparts in passage 1, were mostly
related with extracellular matrix (ECM) formation and biosynthe-
sis of unsaturated fatty acids.Comparing p3 against p1, the biggest
differences in expression were related with metabolism and cell
cycle and the same between p5 and p3. Down-regulated genes
(Table 2, 3 and 4) were involved in migration routes (passage 1
versus isolation) and immunomodulation (passage 3 versus passage
1, and passage 5 versus passage 3). Both the up- and down-
regulated significant genes were highly related between them. In
addition, the Ingenuity Core Analysis found two networks, one for
up-regulated and another for down-regulated, with their associ-
ated functions. Up-regulated network (Fig. 5) showed that FN1,
FGF2, RRAS2, PFN2, SDC1, RPLP0, CHEK1, FAS, WASF1
and GLO1 genes were significantly overexpressed. These genes
were classified into several function categories (BH,0.05), the top
were Regulation of actin cytoskeleton, ECM-receptor interaction,
Cell division signaling pathway, Cell cycle and Ribosome. In the
case of down-regulated network (Fig. 6) were HBEGF, FYN,
PIK3R3, EZR, PI3K, IGF1, STAT5A, GZMB, NFKB1, NFkB,
IL13, CD14, EPOR, HLA-F, B2M, PLCG2, F13A1, IL1R2,
IFNGR1, HLA-DRB1 and IL10RA. These genes were grouped in
functions as Hematopoietic cell lineage, Cell adhesion molecules,
Leucocyte transendothelial migration and Complement and
coagulation cascades. The networks included a subset of the
predicted functional partners and their relationships whose could
be considered to be involved in the maintenance and progression
of hASC culture system.
Discussion
Given the wide clinical potential that hASCs had demonstrated,
our objective was to design a new protocol for the isolation and
maintenance of clinical grade safe cells avoiding xenogeneic
reagents without affecting their characteristics and multipotency.
Use of animal origin reagents is a controversial issue to be taken
into account, because of zoonosis disease transmission. The risk of
prion infection can be avoided by using New Zealand FBS.
However, use of an average of 20% FBS in cell culture, regardless
of the type results in hMSCs carrying between 7 to 30 mg of
bovine serum proteins [45], is able to elicit an immune reaction in
patients [16,46].
In addition, the expression of some murine derived syalic
derivatives was observed in human cells that had been cultured in
contact with mouse fibroblasts, with unknown implications [31].
On the other hand, differences in gene expression levels
between MSCs cultured with FBS versus HS have been reported
[47,48]. This evidence supports the hypothesis that the use of FBS
could affect cell behavior, differentiation or senescence, and
increase the risk of instability. Several groups have tried to solve
the issue by introducing modifications in the protocols such as the
use of autologous HS [49], serum free media [50] or pooled
human platelet lysate [4]. Previously, a protocol has been [46]
developed to eliminate contamination with fetal calf serum,
although this technique is overshadowed by the efficiency of
human derivatives. Partial solutions to the problem were those in
which FBS could be substituted during the isolation and
maintenance of the cells by human AB serum from a donor pool
[21] or the culture using synthetic substitutes [51]. Although these
are great improvements, other animal agents were used during the
isolation and culture, such as BSA or porcine-derived trypsin. In
this context, our efforts are focused also on improving such
protocol by introducing HSA and TrypleH, a non animal reagent
that helps to detach cells. TrypleH has been widely employed in
the literature for detaching and reseeding of cells. In our case, the
cultures did not seem to be altered or compromised by its use and
their karyotype remained normal up to passage 15 (data not
shown).
Table 5. Genes showing expression changes in all passages that were involved in significant KEEG pathways.
Number of genes BH,0.05 KEGG Pathway Genes in KEGG pathway Fisher exact p-value
62 Neurotrophin signalling pathway ARHGDIB, NTRK2,PIK3R3 4.2?1023
doi:10.1371/journal.pone.0067870.t005
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The amendments introduced in our protocol during the
isolation and culture did not compromise the viability, growth or
characteristics of the hASCs obtained. Instead, they did improve
some of these aspects. Use of HS induced high proliferative growth
that increased steadily until passage 18 (33.964.1 HS versus
13.963.3 in FBS). Moreover, the introduction of HS did not
interfere with the hASCs morphology, which retains a character-
istic fibroblast–like morphology and cellular organization [12,20].
This observation was then confirmed at an ultrastructural level
through TEM.
The introduction of wash and spin cycles with HSA during the
isolation, also proved to be beneficial, eliminating the majority of
mature adipocytes.
In addition, we did not observe any increase in the number of
mature adipocytes during the maintenance and expansion of the
cell cultures due to uncontrolled differentiation, indicating that
both the media and the conditions under which the crops are kept
helped preserve cell multipotency. Regarding expression patterns,
detectable levels of mesenchymal stem cell markers were still
observed after expanding the cell cultures 5 times. This result
confirmed that the conditions used for cell maintenance were
adequate to preserve the undifferentiation of hASCs. The
expression of hematopoietic stem cell markers such as CD45 or
CD14, was also detected in the initial stages of isolation and
culture in certain samples but decreased progressively throughout
the passages. This observation was confirmed with the microarray
analysis. At the same time, expression of adipocyte progenitor cell
markers was detected in the culture during isolation and
expansion. These observations indicate that the vast majority, if
not all, of the stem cells present in the culture after the first
passage, had a clear adipose origin and were not derived from
hematopoietic stem cells.
Concerning differentiation studies, our results confirmed that
hASCs cells obtained using our isolation protocol maintain their
multipotent capacity. Detailed ultrastructure and gene analysis of
differentiated cells using TEM revealed that their morphology was
compatible with mature adipocytes and cartilage. In addition, we
wanted to be sure that the culture conditions did not alter hASCs
properties or induce malignization, so we performed microarray
analysis. We observed that in case of up-regulated genes hASCs
cell behavior followed the classical steps for in vitro culture
adaptation. This observation correlates with the proliferation
curve data, which indicates that during passage 5 hASCs are in
exponential growth phase. In summary, expression patterns
indicate that during the initial isolation phase hASCs first adhere
to the culture surface, progressively adapt to the in vitro
environment conditions and finally turn on the proliferation
pathways. We did not detect up-regulation of pathways related
with cell death or senescence in any of the passages. Down-
regulation of gene expression was also analyzed. Immediately
between isolation and the first passage a down regulation of genes
related with migration and proliferation was observed. This result
is coherent with the previous observation that adhesion pathways
were instead up-regulated. Comparison between passage 3 versus
passage 1, and passage 5 versus passage 3, allowed us to detect a
reduction in the expression of biochemical pathways related with
immune reaction. This observation can be explained both by the
progressive elimination of blood cells through the sequential
washing and passaging, and due to the fact that hASCs act in vitro
and in vivo as immunomodulatory cells [22,25,26,52,53]. Micro-
array analysis allowed us to conclude that the changes introduced
trough our protocol, did not compromise their viability, charac-
teristics and potential.
Conclusions
This is the first protocol for hMSCs performed without using
any animal origin reagent. With this work we have proven that
these amendments support the isolation and maintenance of
hASCs, preserving or improving crucial culture parameters such
as viability, cell morphology and identity during long term culture,
as well as proliferation and differentiation ability. To our
knowledge, this is the nearest good manufacture practice condition
protocol developed for hASCs, and it is a low-cost method that can
be routinely and easily used for clinic and research.
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and hematopoietic (CD14, CD117, CD166, CD144) stem cell
markers in hASCs (passage 5) cultured in A) HS and B) FBS
respectively.
(PDF)
Figure S2 Evolution of CD34 and CD45 gene expression
in hASC cultures xenogeneic –free isolated and main-
tained.
(PDF)
Table S1 Primer sequences for the characterization of
isolated hASCs. PCR primers used in the study and conditions.
All of them had been designed using Primer 3 tools. Cartilage
differentiation primers have been performed by Zuk et al., 2002.
(PDF)
Table S2 Microarray gene expression analysis.
(XLS)
Text S1 Supplementary Methods.
(PDF)
Acknowledgments
We are grateful to Dr. Felipe Prosper, Dr. M Jose Escriba´, Jorge Oliver de
la Cruz, Dr. Deborah Burks and Dr. Ruben Moreno for their assistance.
Author Contributions
Conceived and designed the experiments: CEL. Performed the experi-
ments: CEL CG ASG FJE VM AAS JMGV. Analyzed the data: CEL CB
CG ASG FJE VM GF IM ML AAS JMGV. Contributed reagents/
materials/analysis tools: CEL ASG FJE VM IM JMGV. Wrote the paper:
CEL.
References
1. Alvarez PD, Garcia-Arranz M, Georgiev-Hristov T, Garcia-Olmo DA (2008)
New bronchoscopic treatment of tracheomediastinal fistula using autologous
adipose-derived stem cells. Thorax 63: 374–376.
2. Bensidhoum M, Gobin S, Chapel A, Lemaitre G, Bouet S, et al. (2005)
Therapeutic effect of human mesenchymal stem cells in skin after radiation
damage. J Soc Biol 199: 337–341.
3. Bieback K, Ha VA, Hecker A, Grassi M, Kinzebach S, et al. (2010) Altered gene
expression in human adipose stem cells cultured with fetal bovine serum
compared to human supplements. Tissue Eng Part A 16: 3467–3484.
4. Bieback K, Hecker A, Kocao¨mer A, Lannert H, Schallmoser K, et al. (2009)
Human alternatives to fetal bovine serum for the expansion of mesenchymal
stromal cells from bone marrow. Stem Cells 27: 2331–2341.
Xenogeneic-Free Protocol for Adipose Stem Cells
PLOS ONE | www.plosone.org 11 July 2013 | Volume 8 | Issue 7 | e67870
5. Bieback K, Kern S, Kocaomer A, Ferlik K, Bugert P (2008) Comparing
mesenchymal stromal cells from different human tissues: bone marrow, adipose
tissue and umbilical cord blood. Biomed Mater Eng 18: S71–76.
6. Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/
multipotent stromal cells: the state of transdifferentiation and modes of tissue
repair-current views. Stem Cells 25: 2896–2902.
7. Planat-Benard V, Menard C, Andre M, Puceat M, Perez A, et al. (2004)
Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ
Res 94: 223–229.
8. Kern S, Eichler H, Stoeve J, Klu¨ter H, Bieback K (2006) Comparative analysis
of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose
tissue. Stem Cells 24: 1294–1301.
9. Yen BL, Huang HI, Chien CC, Jui HK, Ko BS, et al. (2005) Isolation of
multipotent cells from human term placenta. Stem Cells 23: 3–9.
10. Young HE, Steele TA, Bray RA, Hudson J, Floyd JA, et al. (2001) Human
reserve pluripotent mesenchymal stem cells are present in the connective tissues
of skeletal muscle and dermis derived from fetal, adult, and geriatric donors.
Anat Rec 264: 51–62.
11. Zuk PAZM, Ashjian P, De Ugarte DA, Huang JI, Alfonso ZC, et al. (2002)
Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13:
4279–4295.
12. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, et al. (2001) Multilineage cells
from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:
211–228.
13. Friedenstein AJ, Gorskaja JF, Kulagina NN (1976) Fibroblast precursors in
normal and irradiated mouse hematopoietic organs. Exp Hematol 4: 267–274.
14. Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, et al.
(2003) Autologous stem cell transplantation for treatment of rectovaginal fistula
in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis 18:
451–454.
15. Garcia-Olmo D, Herreros D, De-La-Quintana P, Guadalajara H, Tre´bol J, et
al. (2010) Adipose-derived stem cells in Crohn’s rectovaginal fistula. Case Report
Med 2010: 617–658.
16. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, et al. (1999)
Transplantability and therapeutic effects of bone marrow-derived mesenchymal
cells in children with osteogenesis imperfecta. Nat Med 5: 309–313.
17. Nie C, Yang D, Xu J, Si Z, Jing X, et al. (2011) Locally administered adipose-
derived stem cells accelerate wound healing through differentiation and
vasculogenesis. Cell Transplant 20: 205–216.
18. Sanz-Ruiz R, Ferna´ndez-Santos E, Domı´nguez-Mun˜oa M, Parma R, Villa A, et
al. (2009) Early translation of adipose-derived cell therapy for cardiovascular
disease. Cell Transplant 18: 245–254.
19. Fraser JK, Zhu M, Wulur I, Alfonso Z (2008) Adipose-derived stem cells. In: D.J.
Prockop DGP, and B.A Bunnell, editor. Methods in Molecular Biology. Totowa,
NJ: Humana Press. 59–57.
20. Kuhbier JW, Weyand B, Radtke C, Vogt PM, Casper C, et al. (2010) Isolation,
characterization, differentiation, and application of adipose-derived stem cells.
Adv Biochem Eng Biotechnol 123: 55–105.
21. Kocaoemer A, Kern S, Klu¨ter H, Bieback K (2007) Human AB serum and
thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf
serum for the expansion of mesenchymal stem cells from adipose tissue. Stem
Cells 25: 1270–1278.
22. Yanez R, Oviedo A, Aldea M, Bueren JA, Lamana ML (2010) Prostaglandin E2
plays a key role in the immunosuppressive properties of adipose and bone
marrow tissue-derived mesenchymal stromal cells. Exp Cell Res 316: 3109–
3123.
23. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, et al. (2005)
Immunomodulatory effect of human adipose tissue-derived adult stem cells:
comparison with bone marrow mesenchymal stem cells. Br J Haematol 129:
118–129.
24. Gimble JM, Katz AJ, Bunnell BA (2007) Adipose-derived stem cells for
regenerative medicine. Circ Res 100: 1249–1260.
25. Fang B, Song YP, Li N, Li J, Han Q, et al. (2009) Mesenchymal stem cells for the
treatment of refractory pure red cell aplasia after major ABO-incompatible
hematopoietic stem cell transplantation. Ann Hematol 88: 261–266.
26. Fang B, Song Y, Zhao RC, Han Q, Lin Q (2007) Using human adipose tissue-
derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host
disease resembling acute hepatitis. Transplant Proc 39: 1710–1713.
27. National Institute of Health website. Available: http://www.clinicaltrials.gov.
Accessed 2013 Jun 3.
28. Matsumoto D, Sato K, Gonda K, Takaki Y, Shigeura T, et al. (2006) Cell-
assisted lipotransfer: supportive use of human adipose-derived cells for soft tissue
augmentation with lipoinjection. Tissue Eng Part A 12: 3375–3382.
29. Yoshimura K, Sato K, Aoi N, Kurita M, Hirohi T, et al. (2008) Cell-assisted
lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived
stem/stromal cells. Aesthetic Plast Surg 32: 48–55.
30. Mannello F, Tonti GA (2007) Concise review: no breakthroughs for human
mesenchymal and embryonic stem cell culture: conditioned medium, feeder
layer, or feeder-free; medium with fetal calf serum, human serum, or enriched
plasma; serum-free, serum replacement nonconditioned medium, or ad hoc
formula? All that glitters is not gold! Stem Cells 25: 1603–1609.
31. Martin MJ, Muotri A, Gage F, Varki A (2005) Human embryonic stem cells
express an immunogenic nonhuman sialic acid. Nat Med 11: 228–232.
32. Bihl F, Negro F (2010) Hepatitis E virus: a zoonosis adapting to humans.
J Antimicrob Chemother 65: 817–821.
33. Erickson GA, Bolin SR, Landgraf JG (1991) Viral contamination of fetal bovine
serum used for tissue culture: risks and concerns. Dev Biol Stand 75: 173–175.
34. Knight R (2010) The risk of transmitting prion disease by blood or plasma
products. Transfus Apher Sci 43: 387–391.
35. Willkommen H, Scheiblauer H, Lower J (1999) Serum and serum substitutes:
virus safety by inactivation or removal. Dev Biol Stand 99: 131–138.
36. Organization WH (1997) Medicinal and other products and human and animal
transmissible spongiform encephalopaties: Memorandum from a WHO
meeting. BullWorld Health Organ 75: 505–513.
37. Selvaggi TA, Walker RE, Fleisher TA (1997) Development of antibodies to fetal
calf serum with arthus-like reactions in human immunodeficiency virus-infected
patients given syngeneic lymphocyte infusions. Blood 89: 776–779.
38. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A (2000)
Presence of IgE antibodies to bovine serum albumin in a patient developing
anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer
Immunol Immunother 49: 152–156.
39. R-project software website. Available: http://www.r-project.org/. Accessed
2013 Jun 3.
40. Bioconductor packages website. Available: http://www.bioconductor.org/.
Accessed 2013 Jun 3.
41. Wettenhall JM, Smyth GK (2004) limmaGUI: a graphical user interface for
linear modeling of microarray data. Bioinformatics 20: 3705–3706.
42. Huang dW, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:
44–57.
43. Ingenuity Pathway Analysis website. Available: http://www.ingenuity.com/.
Accessed 2013 Jun 3.
44. Sherman BT, Huang dW, Tan Q, Guo Y, Bour S, et al. (2007) DAVID
Knowledgebase: a gene-centered database integrating heterogeneous gene
annotation resources to facilitate high-throughput gene functional analysis.
BMC Bioinformatics 8: 426.
45. Sundin M, Ringden O, Sundberg B, Nava S, Go¨therstro¨m C, et al. (2007) No
alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf
serum antibodies, after transplantation in allogeneic hematopoietic stem cell
recipients. Haematologica 92: 1208–1215.
46. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, et al. (2004) Internalized
antigens must be removed to prepare hypoimmunogenic mesenchymal stem
cells for cell and gene therapy. Mol Ther 9: 747–756.
47. Shahdadfar A, Fronsdal K, Haug T (2005) In vitro expansion of human
mesenchymal stem cells: choice of serum is a determinant of cell proliferation,
differentiation, gene expression, and transcriptome stability. Stem Cells 23:
1357–1366.
48. Lindroos B, Aho K-L, Kuokkanen H, Ra¨ty S, Huhtala H, et al. (2010)
Differential gene expression in adipose stem cells cultured in allogeneic human
serum versus fetal bovine serum. Tissue Eng Part A 7: 2281–2294.
49. Stute N, Holtz K, Bubenheim M, Lange C, Blake F, et al. (2004) Autologous
serum for isolation and expansion of human mesenchymal stem cells for clinical
use. Exp Hematol 32: 1212–1225.
50. Muller I, Kordowich S, Holzwarth C, Spano C, Isensee G, et al. (2006) Animal
serum-free culture conditions for isolation and expansion of multipotent
mesenchymal stromal cells from human BM. Cytotherapy 8: 437–444.
51. Dromard C, Bourin P, Andre M, De Barros S, Casteilla L, et al. (2011) Human
adipose derived stroma/stem cells grow in serum-free medium as floating
spheres. Exp Cell Res 317: 770–780.
52. Le Blanc K, Gotherstrom C, Ringden O, Hassan M, McMahon R, et al. (2005)
Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation
in a patient with severe osteogenesis imperfecta. Transplantation 79: 1607–1614.
53. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, et al. (2006)
Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive
properties applicable for the control of the graft-versus-host disease. Stem Cells
24: 2582–2591.
Xenogeneic-Free Protocol for Adipose Stem Cells
PLOS ONE | www.plosone.org 12 July 2013 | Volume 8 | Issue 7 | e67870
